Multi-Target T Cells for Pediatric Brain Tumors: Why the Phase 1 News Matters

What the trial was

The study is called ReMIND, registered as NCT03652545 and led by Children's National Research Institute. Its results were published in Nature Medicine on June 30, 2026.

It was an open-label, phase 1, adaptive dose-finding trial. Phase 1 means the main questions were safety, feasibility, and dose. Adaptive dose-finding means the dose was adjusted as the trial went along.

Central nervous system tumors are the deadliest cancers in children. That is the reason a trial like this is run at all.

What was given

The treatment is a T-cell therapy, but not the kind most people have heard of.

NCI describes T-cell transfer therapy as collecting a person's own immune cells, growing large numbers of them in a laboratory, and returning them through a vein. In CAR T-cell therapy, the cells are genetically changed first so they carry a new receptor.

These T cells were not genetically engineered. They were autologous, meaning they came from the patient, and they were trained in the laboratory to recognize three proteins found on many pediatric brain tumors: WT1, PRAME, and survivin.

Targeting three at once is deliberate. Tumors vary from cell to cell and can shift under pressure from treatment, so a single target can be evaded.

The cells were given into the bloodstream. Children's National notes this is unusual: many other brain tumor immunotherapies require injection directly into the brain or spinal fluid.

Who took part

The trial ran three arms, and the difference between enrolled and infused matters.

• Arm A. Newly diagnosed diffuse intrinsic pontine glioma, without lymphodepletion. Sixteen enrolled, eleven infused.
• Arm B. Relapsed or recurrent non-brainstem CNS cancers, without lymphodepletion. Twenty-eight enrolled, eighteen infused.
• Arm C. The same relapsed group, with lymphodepletion. Seven enrolled, four infused.

Lymphodepletion means clearing out existing immune cells with chemotherapy first, to give transferred cells room to work.

Across all three arms, 51 children enrolled and 33 received cells. That gap is itself a phase 1 finding: manufacturing a cell product for a specific child does not always succeed in time.

What it found

The maximum tolerated dose was dose level 3, which is 8 × 10⁷ cells per square meter of body surface per dose.

Treatment was well tolerated. Fatigue and headache were the most common side effects. Two serious events of tumor swelling were considered possibly related to the treatment.

One death, graded 5, was classed as a dose-limiting toxicity. It occurred in a child with diffuse intrinsic pontine glioma who had hydrocephalus, tumor swelling, and respiratory failure.

On the efficacy side, which was a secondary question:

• Median overall survival in arm A was 13.7 months from diagnosis, with a range from 6.2 to 32.0 months.
• Median progression-free survival in arms B and C was 5.0 months from infusion, with a range from 0.5 to 51.6 months.
• Three children in arms B and C were alive without disease at 31.8, 41.2, and 51.6 months, with no further treatment. One had a complete response.

The authors' own conclusion is measured: the trial met its safety and feasibility endpoints, with some preliminary signals of efficacy.

How to read a phase 1 result

The three long-term survivors are the part that travels, and they are worth understanding properly.

Three children out of 22 infused in arms B and C had an outcome that would be very unusual for recurrent brain tumors. That is a genuine signal and a reason to run a larger trial. It is not a response rate, and a phase 1 trial with no control group cannot say why those three did well.

The median figures sit alongside them. A median progression-free survival of 5.0 months means half the group had the cancer grow again within five months.

Both facts came out of the same trial. Reporting one without the other is how a phase 1 result gets misread. Our explainer on clinical trial phases covers what each phase can and cannot establish.

When to get checked

Nothing in this trial changes what to do about symptoms in a child. Brain tumor symptoms depend on where the tumor sits, and they are usually noticed by a parent before anyone else.

NCI says to check with a child's doctor about:

• A morning headache, or a headache that goes away after vomiting.
• Nausea and vomiting.
• Problems with vision, hearing, or speech.
• Loss of balance and trouble walking.
• Handwriting that is getting worse, or slowed speech.
• Weakness, or a change in feeling on one side of the body.
• Unusual sleepiness, or more or less energy than usual.
• A change in personality or behavior.
• Seizures.
• Weight loss or weight gain with no known cause.
• In infants, an increase in the size of the head.

NCI adds the reassurance and the instruction in one line: these symptoms may be caused by conditions other than a brain tumor, and the only way to know is to see the doctor.

For families weighing a trial, our page on clinical trials versus standard treatment explains the difference in goals.

What this does not mean

• It does not mean this therapy is FDA approved for pediatric brain tumors. It is not.
• It does not mean the treatment is available outside a clinical trial.
• It does not mean every child with a brain tumor would be eligible. The arms were defined narrowly, by tumor type and by whether the disease was new or recurrent.
• It does not show that the therapy works better than standard care. There was no comparison group, and answering that needs a randomized trial.
• One death in the trial was classed as a dose-limiting toxicity. "Well tolerated" is the authors' phrase for the group, not a guarantee for an individual.

Sources

• Gomez S, DiCioccio RA, et al., Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial, Nat Med 2026;32(7):2481-2493 (NCBI E-utilities record)
• ClinicalTrials.gov record for NCT03652545 (ReMIND)
• Children's National: First-of-its-kind cell therapy clinical trial shows promising long-term survival in children with aggressive brain tumors
• NCI: T-cell Transfer Therapy
• NCI PDQ: Childhood Glioma (Including Astrocytoma) Treatment

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.